Mitsubishi UFJ Trust & Banking Corp Sells 223,792 Shares of Edwards Lifesciences Corporation $EW

Mitsubishi UFJ Trust & Banking Corp trimmed its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 21.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 832,695 shares of the medical research company’s stock after selling 223,792 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned 0.14% of Edwards Lifesciences worth $65,125,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Jennison Associates LLC lifted its stake in shares of Edwards Lifesciences by 15.7% in the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock valued at $912,788,000 after purchasing an additional 1,584,958 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Edwards Lifesciences by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock valued at $491,673,000 after buying an additional 264,311 shares during the period. Nuveen LLC bought a new stake in Edwards Lifesciences in the first quarter worth $330,881,000. Invesco Ltd. boosted its stake in Edwards Lifesciences by 2.6% during the first quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock worth $310,773,000 after buying an additional 107,241 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Edwards Lifesciences by 5.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock valued at $287,140,000 after acquiring an additional 198,882 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Citigroup raised their target price on shares of Edwards Lifesciences from $95.00 to $96.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Wells Fargo & Company raised their price objective on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research note on Thursday, August 7th. Deutsche Bank Aktiengesellschaft boosted their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, July 25th. Evercore ISI increased their price target on Edwards Lifesciences from $88.00 to $92.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Finally, National Bankshares set a $92.00 price objective on Edwards Lifesciences in a report on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $91.39.

Edwards Lifesciences Stock Performance

EW stock opened at $85.55 on Thursday. The firm has a 50-day simple moving average of $77.99 and a two-hundred day simple moving average of $77.59. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a one year low of $65.31 and a one year high of $87.09. The firm has a market cap of $49.65 billion, a price-to-earnings ratio of 12.31, a PEG ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the prior year, the company posted $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the transaction, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,314,725.84. The trade was a 24.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 22,970 shares of company stock worth $1,862,878. 0.34% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.